Positron emission topography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma

Darren B. Schneider, Carolyn Clary-Macy, Sudha Challa, Kent C. Sasse, Scott H. Merrick, Randall Hawkins, Gary R Caputo, David Jablons

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Objectives: The purpose of this study was to evaluate the utility of positron emission tomography with F18-fluorodeoxyglucose in the preoperative evaluation and staging of malignant mesothelioma in patients who were candidates for aggressive combined modality therapy. Methods: Eighteen consecutive patients with biopsy-proven malignant mesothelioma underwent positron emission tomographic scanning. The results of positron emission tomographic imaging were compared with results obtained by computed tomography, mediastinoscopy, thoracoscopy, and pathologic examination of surgical specimens. All patients fasted and received an average of 14.5 ± 2.7 mCi of F18-fluorodeoxyglucose for positron emission tomographic scanning. Attenuation-corrected whole-body and regional emission images of the chest and upper abdomen were acquired and formatted into transaxial, coronal, and sagittal images. Results: All primary malignant mesotheliomas accumulated F18-fluorodeoxyglucose, and the mean standardized uptake value was 7.6 (range, 3.33-14.85; n = 9). There were no false-negative results of positron emission tomography. Identification of occult extrathoracic metastases by positron emission tomography was the basis for excluding two patients from surgical therapy. There were two false-positive results of positron emission tomography: increased F18-fluorodeoxyglucose uptake in the contralateral chest that was negative by thoracoscopic biopsy (n = 1) and increased abdominal F18-fluorodeoxyglucose uptake after partial colectomy for diverticular disease (n = 1). Conclusions: Positron emission tomography can identify malignant pleural mesothelioma and appears to be a useful noninvasive staging modality for patients being considered for aggressive combined modality therapy.

Original languageEnglish (US)
Pages (from-to)128-133
Number of pages6
JournalJournal of Thoracic and Cardiovascular Surgery
Volume120
Issue number1
StatePublished - Jul 2000
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Positron-Emission Tomography
Electrons
Combined Modality Therapy
Thorax
Mediastinoscopy
Biopsy
Thoracoscopy
Colectomy
Abdomen
Tomography
Malignant Mesothelioma
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Schneider, D. B., Clary-Macy, C., Challa, S., Sasse, K. C., Merrick, S. H., Hawkins, R., ... Jablons, D. (2000). Positron emission topography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular Surgery, 120(1), 128-133.

Positron emission topography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. / Schneider, Darren B.; Clary-Macy, Carolyn; Challa, Sudha; Sasse, Kent C.; Merrick, Scott H.; Hawkins, Randall; Caputo, Gary R; Jablons, David.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 120, No. 1, 07.2000, p. 128-133.

Research output: Contribution to journalArticle

Schneider, DB, Clary-Macy, C, Challa, S, Sasse, KC, Merrick, SH, Hawkins, R, Caputo, GR & Jablons, D 2000, 'Positron emission topography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma', Journal of Thoracic and Cardiovascular Surgery, vol. 120, no. 1, pp. 128-133.
Schneider, Darren B. ; Clary-Macy, Carolyn ; Challa, Sudha ; Sasse, Kent C. ; Merrick, Scott H. ; Hawkins, Randall ; Caputo, Gary R ; Jablons, David. / Positron emission topography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. In: Journal of Thoracic and Cardiovascular Surgery. 2000 ; Vol. 120, No. 1. pp. 128-133.
@article{4dafc2b1f71544f8adc7feadabac6636,
title = "Positron emission topography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma",
abstract = "Objectives: The purpose of this study was to evaluate the utility of positron emission tomography with F18-fluorodeoxyglucose in the preoperative evaluation and staging of malignant mesothelioma in patients who were candidates for aggressive combined modality therapy. Methods: Eighteen consecutive patients with biopsy-proven malignant mesothelioma underwent positron emission tomographic scanning. The results of positron emission tomographic imaging were compared with results obtained by computed tomography, mediastinoscopy, thoracoscopy, and pathologic examination of surgical specimens. All patients fasted and received an average of 14.5 ± 2.7 mCi of F18-fluorodeoxyglucose for positron emission tomographic scanning. Attenuation-corrected whole-body and regional emission images of the chest and upper abdomen were acquired and formatted into transaxial, coronal, and sagittal images. Results: All primary malignant mesotheliomas accumulated F18-fluorodeoxyglucose, and the mean standardized uptake value was 7.6 (range, 3.33-14.85; n = 9). There were no false-negative results of positron emission tomography. Identification of occult extrathoracic metastases by positron emission tomography was the basis for excluding two patients from surgical therapy. There were two false-positive results of positron emission tomography: increased F18-fluorodeoxyglucose uptake in the contralateral chest that was negative by thoracoscopic biopsy (n = 1) and increased abdominal F18-fluorodeoxyglucose uptake after partial colectomy for diverticular disease (n = 1). Conclusions: Positron emission tomography can identify malignant pleural mesothelioma and appears to be a useful noninvasive staging modality for patients being considered for aggressive combined modality therapy.",
author = "Schneider, {Darren B.} and Carolyn Clary-Macy and Sudha Challa and Sasse, {Kent C.} and Merrick, {Scott H.} and Randall Hawkins and Caputo, {Gary R} and David Jablons",
year = "2000",
month = "7",
language = "English (US)",
volume = "120",
pages = "128--133",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Positron emission topography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma

AU - Schneider, Darren B.

AU - Clary-Macy, Carolyn

AU - Challa, Sudha

AU - Sasse, Kent C.

AU - Merrick, Scott H.

AU - Hawkins, Randall

AU - Caputo, Gary R

AU - Jablons, David

PY - 2000/7

Y1 - 2000/7

N2 - Objectives: The purpose of this study was to evaluate the utility of positron emission tomography with F18-fluorodeoxyglucose in the preoperative evaluation and staging of malignant mesothelioma in patients who were candidates for aggressive combined modality therapy. Methods: Eighteen consecutive patients with biopsy-proven malignant mesothelioma underwent positron emission tomographic scanning. The results of positron emission tomographic imaging were compared with results obtained by computed tomography, mediastinoscopy, thoracoscopy, and pathologic examination of surgical specimens. All patients fasted and received an average of 14.5 ± 2.7 mCi of F18-fluorodeoxyglucose for positron emission tomographic scanning. Attenuation-corrected whole-body and regional emission images of the chest and upper abdomen were acquired and formatted into transaxial, coronal, and sagittal images. Results: All primary malignant mesotheliomas accumulated F18-fluorodeoxyglucose, and the mean standardized uptake value was 7.6 (range, 3.33-14.85; n = 9). There were no false-negative results of positron emission tomography. Identification of occult extrathoracic metastases by positron emission tomography was the basis for excluding two patients from surgical therapy. There were two false-positive results of positron emission tomography: increased F18-fluorodeoxyglucose uptake in the contralateral chest that was negative by thoracoscopic biopsy (n = 1) and increased abdominal F18-fluorodeoxyglucose uptake after partial colectomy for diverticular disease (n = 1). Conclusions: Positron emission tomography can identify malignant pleural mesothelioma and appears to be a useful noninvasive staging modality for patients being considered for aggressive combined modality therapy.

AB - Objectives: The purpose of this study was to evaluate the utility of positron emission tomography with F18-fluorodeoxyglucose in the preoperative evaluation and staging of malignant mesothelioma in patients who were candidates for aggressive combined modality therapy. Methods: Eighteen consecutive patients with biopsy-proven malignant mesothelioma underwent positron emission tomographic scanning. The results of positron emission tomographic imaging were compared with results obtained by computed tomography, mediastinoscopy, thoracoscopy, and pathologic examination of surgical specimens. All patients fasted and received an average of 14.5 ± 2.7 mCi of F18-fluorodeoxyglucose for positron emission tomographic scanning. Attenuation-corrected whole-body and regional emission images of the chest and upper abdomen were acquired and formatted into transaxial, coronal, and sagittal images. Results: All primary malignant mesotheliomas accumulated F18-fluorodeoxyglucose, and the mean standardized uptake value was 7.6 (range, 3.33-14.85; n = 9). There were no false-negative results of positron emission tomography. Identification of occult extrathoracic metastases by positron emission tomography was the basis for excluding two patients from surgical therapy. There were two false-positive results of positron emission tomography: increased F18-fluorodeoxyglucose uptake in the contralateral chest that was negative by thoracoscopic biopsy (n = 1) and increased abdominal F18-fluorodeoxyglucose uptake after partial colectomy for diverticular disease (n = 1). Conclusions: Positron emission tomography can identify malignant pleural mesothelioma and appears to be a useful noninvasive staging modality for patients being considered for aggressive combined modality therapy.

UR - http://www.scopus.com/inward/record.url?scp=0034214834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034214834&partnerID=8YFLogxK

M3 - Article

C2 - 10884665

AN - SCOPUS:0034214834

VL - 120

SP - 128

EP - 133

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 1

ER -